Citadel Advisors
APRE icon

Citadel Advisors’s Aprea Therapeutics APRE Stock Holding History

Citadel Advisors’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-585
Closed -$3.77K – 14669
2022
Q4 		$3.77K Sell
585
-5
-0.8% -$53 ﹤0.01% 14173
2022
Q3 		$8K Sell
590
-10
-2% -$177 ﹤0.01% 12308
2022
Q2 		$9K Buy
+600
New +$13.8K ﹤0.01% 12602
2022
Q1 		– Sell
-2,605
Closed -$150K – 13514
2021
Q4 		$150K Sell
2,605
-2,720
-51% -$240K ﹤0.01% 12252
2021
Q3 		$544K Buy
5,325
+3,235
+155% +$294K ﹤0.01% 9656
2021
Q2 		$204K Buy
2,090
+935
+81% +$86.4K ﹤0.01% 12113
2021
Q1 		$118K Buy
+1,155
New +$135K ﹤0.01% 12315

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors's APRE Position: Q2 2026 in Review

Citadel Advisors opened a new position in Aprea Therapeutics (APRE) in Q2 2026: 58,600 shares worth $47K. The stake represents ﹤0.01% of the portfolio and ranks #13143 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in APRE as recently as Q4 2025.

Citadel Advisors first reported a position in APRE in Q4 2019 and has held it in 13 quarters since. The position peaked at $14.2M in Q4 2019. 28 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

  • Citadel Advisors held 58,600 shares of Aprea Therapeutics worth $47K as of Q2 2026.
  • Aprea Therapeutics was a new Citadel Advisors position in Q2 2026.
  • Aprea Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13143 holding.
  • Citadel Advisors first reported a position in Aprea Therapeutics in Q4 2019 and has held it in 13 quarters since.
  • Citadel Advisors's Aprea Therapeutics position peaked at $14.2M in Q4 2019.
  • 28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.